Adaptive Biotechnologies (ADPT) Receivables - Other (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Receivables - Other data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Receivables - Other rose 6.67% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 6.67% YoY) and the FY2025 annual result came in at $1.5 million, up 15.38% from the prior year.
• Receivables - Other improved to $1.6 million in Q1 2026 per ADPT's latest filing, from $1.5 million in the prior quarter.
• The five-year high for Receivables - Other was $1.6 million in Q1 2026, with the low at $800000.0 in Q2 2022.
• Average Receivables - Other over 5 years is $1.2 million, with a median of $1.1 million recorded in 2022.
• Year-over-year, Receivables - Other sank 65.22% in 2022 and jumped 36.36% in 2025.
• Adaptive Biotechnologies' Receivables - Other stood at $800000.0 in 2022, then grew by 25.0% to $1.0 million in 2023, then rose by 30.0% to $1.3 million in 2024, then gained by 15.38% to $1.5 million in 2025, then climbed by 6.67% to $1.6 million in 2026.
• Business Quant data shows ADPT's Receivables - Other at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.